Oligodendroglioma historical perspective: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
| Line 15: | Line 15: | ||
*Their name is derived from the Greek words "''oligo''" meaning few and "''dendro''" meaning trees | *Their name is derived from the Greek words "''oligo''" meaning few and "''dendro''" meaning trees | ||
*In 2009, Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation<ref name="history">Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma</ref> | *In 2009, Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation<ref name="history">Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma</ref> | ||
*2009 ASCO Annual Meeting, suggests that PCV therapy may be superior in efficacy to the newer temozolomide therapy. Median time to progression for patients with 1p19q co-deletion was longer following PCV alone (7.6 years) than with temozolomide alone (3.3 years); median overall survival was also longer with PCV treatment versus temozolomide treatment (not reached, vs. 7.1 years) | |||
*[[radiation|Irradiation]] of [[pituitary adenoma]] was also discovered to be associated with oligodendroglioma by Kevin Smith et al | *[[radiation|Irradiation]] of [[pituitary adenoma]] was also discovered to be associated with oligodendroglioma by Kevin Smith et al | ||
*As of the 2016 edition of the WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters | *As of the 2016 edition of the WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters | ||
Revision as of 22:09, 7 May 2019
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma historical perspective On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma historical perspective |
|
Risk calculators and risk factors for Oligodendroglioma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
The term "oligodendroglioma" was first coined by Bailey and Cushing in 1926 following the observation that the tumor cells are morphologically similar to oligodendrocytes. Oligodendroglioma was first described and published by W. E. Carnegie Dickson in 1926. In 2009, NJDS mutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al.
Historical Perspective
- The term "oligodendroglioma" was first coined by Bailey and Cushing in 1926 following the observation that the tumor cells are morphologically similar to oligodendrocytes[1]
- The classification and grading of gliomas have evolved over time, beginning in 1926 with a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others
- Westergaard's study (1997) showed that patients younger than 20 years had a median survival of 17.5 years[2]
- Modern classification of gliomas is based on the World Health Organization (WHO) Classification of Central Nervous System Tumors, first published in 1979 and revised four times since then, most recently in 2016
- Oligodendroglioma was first described and published by W. E. Carnegie Dickson in 1926[3]
- Their name is derived from the Greek words "oligo" meaning few and "dendro" meaning trees
- In 2009, Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation[4]
- 2009 ASCO Annual Meeting, suggests that PCV therapy may be superior in efficacy to the newer temozolomide therapy. Median time to progression for patients with 1p19q co-deletion was longer following PCV alone (7.6 years) than with temozolomide alone (3.3 years); median overall survival was also longer with PCV treatment versus temozolomide treatment (not reached, vs. 7.1 years)
- Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al
- As of the 2016 edition of the WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters
References
- ↑ Hartmann C, von Deimling A (2009). "Molecular pathology of oligodendroglial tumors". Recent Results Cancer Res. 171: 25–49. doi:10.1007/978-3-540-31206-2_2. PMID 19322536.
- ↑ Engelhard, Herbert H; Stelea, Ana; Mundt, Arno (2003). "Oligodendroglioma and anaplastic oligodendroglioma:". Surgical Neurology. 60 (5): 443–456. doi:10.1016/S0090-3019(03)00167-8. ISSN 0090-3019.
- ↑ Dickson, WEC (1926), Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle, Brain-A journal of neurology, p. 578, retrieved 11/20/2015 Check date values in:
|accessdate=(help) - ↑ Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma